| MeSH term | MeSH ID | Detail |
|---|---|---|
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Stomach Neoplasms | D013274 | 24 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Surgical Wound Infection | D013530 | 7 associated lipids |
| Abscess | D000038 | 13 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Gastritis | D005756 | 27 associated lipids |
| Heart Failure | D006333 | 36 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- Clin. Infect. Dis. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Paul P et al. | Capillary electrophoresis with capacitively coupled contactless conductivity detection method development and validation for the determination of azithromycin, clarithromycin, and clindamycin. | 2017 | J Sep Sci | pmid:28683179 |
| Jenkins H et al. | Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. | 2017 | Clin Drug Investig | pmid:27928738 |
| Mishima E et al. | Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. | 2017 | Intern. Med. | pmid:28674358 |
| Sun W et al. | Synergistic drug combination effectively blocks Ebola virus infection. | 2017 | Antiviral Res. | pmid:27890675 |
| Shimoyama T et al. | Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. | 2017 | Intern. Med. | pmid:28674348 |
| Hung IFN et al. | Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. | 2017 | Chest | pmid:27884765 |
| Ustundag GH et al. | The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. | 2017 | Can J Gastroenterol Hepatol | pmid:28656129 |
| Peng X et al. | Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. | 2017 | Int J Med Sci | pmid:28638276 |
| Ozturk O et al. | Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. | 2017 | Arab J Gastroenterol | pmid:28601610 |
| Aguilera-Correa JJ et al. | Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. | 2017 | Diagn. Microbiol. Infect. Dis. | pmid:27863951 |
| Alirezaei A et al. | Helicobacter pylori Eradication With Levofloxacin or Clarithromycin in Dialysis Versus Nonuremic Patients. | 2017 | Iran J Kidney Dis | pmid:28575885 |
| Katayama Y et al. | Neuroprotective effects of clarithromycin against neuronal damage in cerebral ischemia and in cultured neuronal cells after oxygen-glucose deprivation. | 2017 | Life Sci. | pmid:27825902 |
| Cosme A et al. | Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. | 2017 | World J. Gastroenterol. | pmid:28566898 |
| Moj D et al. | Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens. | 2017 | AAPS J | pmid:27822600 |
| Angol DC et al. | from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. | 2017 | Biomed Res Int | pmid:28555193 |
| Akpinar Z et al. | Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth. | 2017 | Arab J Gastroenterol | pmid:28532623 |
| Beckman E et al. | A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate. | 2017 | J. Clin. Microbiol. | pmid:28515219 |
| Kajihara Y et al. | Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. | 2017 | Scand. J. Gastroenterol. | pmid:27806639 |
| Yan J et al. | Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital. | 2017 | Eur Arch Otorhinolaryngol | pmid:28508178 |
| Shaulov A et al. | Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy. | 2017 | Am. J. Hematol. | pmid:27804150 |
| DaCosta A et al. | Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients. | 2017 | J. Cyst. Fibros. | pmid:28495380 |
| Malfertheiner P et al. | Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. | 2017 | Gut | pmid:27707777 |
| Sharifi R et al. | Dietary PUFA Increase Apoptosis in Stomach of Patients with Dyspeptic Symptoms and Infected with H. pylori. | 2017 | Lipids | pmid:28493185 |
| Morimoto K et al. | A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013. | 2017 | Ann Am Thorac Soc | pmid:27788025 |
| Reddy AB and Reddy ND | Development of Multiple-Unit Floating Drug Delivery System of Clarithromycin: Formulation, in vitro Dissolution by Modified Dissolution Apparatus, in vivo Radiographic Studies in Human Volunteers. | 2017 | Drug Res (Stuttg) | pmid:28449156 |
| Aktas AH and Saridag AM | Liquid Chromatographic-Chemometric Techniques for the Simultaneous HPLC Determination of Lansoprazole, Amoxicillin and Clarithromycin in Commercial Preparation. | 2017 | J Chromatogr Sci | pmid:28449104 |
| Itskoviz D et al. | Smoking increases the likelihood of Helicobacter pylori treatment failure. | 2017 | Dig Liver Dis | pmid:28427781 |
| Koštrun S et al. | Around the macrolide - Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation. | 2017 | Eur J Med Chem | pmid:28410508 |
| Wong AYS et al. | Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis. | 2017 | Drug Saf | pmid:28397186 |
| Aziz DB et al. | Rifabutin Is Active against Mycobacterium abscessus Complex. | 2017 | Antimicrob. Agents Chemother. | pmid:28396540 |
| Ivanová L et al. | Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka. | 2017 | Environ. Res. | pmid:28183039 |
| Giguère S et al. | Antimicrobial Resistance in . | 2017 | Microbiol Spectr | pmid:29052538 |
| Varma MV et al. | Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. | 2017 | Clin. Pharmacol. Ther. | pmid:27648490 |
| Huet D et al. | [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. | 2017 | Rev Mal Respir | pmid:27639948 |
| El Haj C et al. | The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance? | 2017 | Med. Microbiol. Immunol. | pmid:27639707 |
| Jia L et al. | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. | 2017 | Bioorg. Med. Chem. Lett. | pmid:28711353 |
| Seyama S et al. | Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). | 2017 | J. Antimicrob. Chemother. | pmid:27999037 |
| Zerbetto De Palma G et al. | Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. | 2017 | Microb. Drug Resist. | pmid:27391421 |
| Giguère S | Treatment of Infections Caused by Rhodococcus equi. | 2017 | Vet. Clin. North Am. Equine Pract. | pmid:28161038 |
| Berni E et al. | Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. | 2017 | BMJ Open | pmid:28115334 |
| Legendre T et al. | [Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. | 2017 | Encephale | pmid:27178256 |
| Choi HS et al. | Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. | 2017 | Jpn. J. Infect. Dis. | pmid:27169951 |
| Serrano CA et al. | Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. | 2017 | J. Pediatr. Gastroenterol. Nutr. | pmid:27159208 |
| Yatera K et al. | The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. | 2017 | Respir Investig | pmid:29153420 |
| Lee MC et al. | Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. | 2017 | J. Antimicrob. Chemother. | pmid:29091186 |
| Costa S et al. | Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. | 2017 | Eur J Gastroenterol Hepatol | pmid:28877088 |
| Pryjma M et al. | Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. | 2017 | Antimicrob. Agents Chemother. | pmid:28874379 |
| Santos RP et al. | induced rash and mucositis: a recently described entity. | 2017 | BMJ Case Rep | pmid:28830900 |
| Takahashi C et al. | Morphological study of efficacy of clarithromycin-loaded nanocarriers for treatment of biofilm infection disease. | 2017 | Med Mol Morphol | pmid:27119723 |
| Kwon S et al. | [The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in Eradication]. | 2017 | Korean J Gastroenterol | pmid:28830132 |
| Laidler N | Cutaneous infection with paucibacillary treated successfully with a modified antituberculous drug regimen. | 2017 | BMJ Case Rep | pmid:29275384 |
| Lee JS et al. | Implication of species change of Nontuberculous Mycobacteria during or after treatment. | 2017 | BMC Pulm Med | pmid:29262802 |
| Ruiter R et al. | Helicobacter pylori resistance in the Netherlands: a growing problem? | 2017 | Neth J Med | pmid:29219812 |
| Pastukh N et al. | GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. | 2017 | Helicobacter | pmid:29058343 |
| Tognetti L et al. | Bullous impetigo during interstitial pneumonitis. | 2017 | G Ital Dermatol Venereol | pmid:29050448 |
| Chen MJ et al. | Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. | 2017 | J. Antimicrob. Chemother. | pmid:28961996 |
| Kim SY et al. | Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. | 2017 | Helicobacter | pmid:28940815 |
| Mukherjee D et al. | Vancomycin and Clarithromycin Show Synergy against . | 2017 | Antimicrob. Agents Chemother. | pmid:28923867 |
| Tsay FW et al. | A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. | 2017 | Antimicrob. Agents Chemother. | pmid:28807915 |
| Oh ES et al. | Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. | 2017 | J Clin Pharm Ther | pmid:28806472 |
| Kuo YT et al. | Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. | 2017 | Lancet Gastroenterol Hepatol | pmid:28781119 |
| Ramas M et al. | Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. | 2017 | Gastroenterol Hepatol | pmid:28780968 |
| Painsi C and Lange-Asschenfeldt B | Image Gallery: Pink papules within a tattoo linked to Mycobacterium chelonae infection. | 2017 | Br. J. Dermatol. | pmid:28731256 |
| Fremlin GA et al. | Clarithromycin, rifampicin and fusidic acid triple combination therapy for chronic folliculocentric pustulosis of the scalp. | 2017 | Clin. Exp. Dermatol. | pmid:28691163 |
| Antonakos N et al. | Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. | 2017 | Crit Care | pmid:28274246 |
| Koratala A et al. | Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. | 2017 | Blood Purif. | pmid:28268216 |
| Lin CM et al. | Is ionizing radiation a risk factor to diffuse panbronchiolitis? | 2017 | QJM | pmid:28069906 |
| Fraser AG | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776748 |
| Jung YS et al. | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776746 |
| Makihara K et al. | Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. | 2017 | Cancer Chemother. Pharmacol. | pmid:28711984 |
| Tanabe H et al. | Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. | 2017 | Dig. Dis. Sci. | pmid:28664410 |
| Fohner AE et al. | PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. | 2017 | Pharmacogenet. Genomics | pmid:28146011 |
| Sue S et al. | The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. | 2017 | Intern. Med. | pmid:28566587 |
| Mougari F et al. | Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. | 2017 | Antimicrob. Agents Chemother. | pmid:27799212 |
| Hu Y et al. | Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance. | 2017 | Front Cell Infect Microbiol | pmid:28529929 |
| Jeong SH et al. | Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. | 2017 | Int. J. Infect. Dis. | pmid:28522316 |
| Kishida D et al. | Intractable Cutaneous Nontuberculous Mycobacteriosis (Mycobacterium abscessus) during Treatment for Systemic Lupus Erythematosus. | 2017 | Intern. Med. | pmid:28502947 |
| Jung YS et al. | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. | 2017 | Aliment. Pharmacol. Ther. | pmid:28497487 |
| Sharman MJ et al. | Gastrokine mRNA expression in gastric tissue from dogs with helicobacter colonisation but without inflammatory change during treatment. | 2017 | Vet. Immunol. Immunopathol. | pmid:28494926 |
| O'Brien CR et al. | Feline leprosy due to Candidatus 'Mycobacterium tarwinense':Further clinical and molecular characterisation of 15 previously reported cases and an additional 27 cases | 2017 | J. Feline Med. Surg. | pmid:28438086 |
| Tan B et al. | Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. | 2017 | PLoS ONE | pmid:28407007 |
| Freyne B and Curtis N | Mycobacterium gordonae Skin Infection in an Immunocompetent Child. | 2017 | Pediatr. Infect. Dis. J. | pmid:28403059 |
| Bustamante-Rengifo JA et al. | Effect of treatment failure on the CagA EPIYA motif in strains from Colombian subjects. | 2017 | World J. Gastroenterol. | pmid:28373764 |
| Sakurai K et al. | Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. | 2017 | World J. Gastroenterol. | pmid:28216974 |
| Awan S et al. | Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. | 2017 | Lung Cancer | pmid:28213005 |
| Su J et al. | Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. | 2017 | Medicine (Baltimore) | pmid:28207505 |
| Branquinho D et al. | Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? | 2017 | BMC Gastroenterol | pmid:28202013 |
| Inukai K et al. | Effect of gel formation on the dissolution behavior of clarithromycin tablets. | 2017 | Int J Pharm | pmid:28196716 |
| Miftahussurur M et al. | Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic. | 2017 | Am. J. Trop. Med. Hyg. | pmid:28193745 |
| Zhang Z et al. | In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. | 2017 | Int. J. Antimicrob. Agents | pmid:28188830 |
| Kristin F et al. | Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. | 2017 | Eur J Pharm Sci | pmid:28179133 |
| Chen D et al. | Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. | 2017 | Antimicrob. Agents Chemother. | pmid:28167563 |
| Olesen JS et al. | Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy. | 2017 | BMJ Case Rep | pmid:28137898 |
| Chang JY et al. | Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. | 2017 | BMC Gastroenterol | pmid:28109257 |
| Sasaoka Y et al. | Neonatal apnea with Chlamydia pneumoniae infection. | 2017 | Pediatr Int | pmid:28102626 |
| Lapa GB et al. | Two approaches to the use of benzo[c][1,2]oxaboroles as active fragments for synthetic transformation of clarithromycin. | 2017 | J Enzyme Inhib Med Chem | pmid:28097898 |
| Chen PY et al. | Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074519 |
| Zamani M et al. | Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074507 |
| Chey WD et al. | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. | 2017 | Am. J. Gastroenterol. | pmid:28071659 |
| Ko J et al. | Delayed onset Mycobacterium intracellulare keratitis after laser in situ keratomileusis: A case report and literature review. | 2017 | Medicine (Baltimore) | pmid:29390522 |